Total Payments
$466,716
2024 Payments
$70,880
Companies
30
Transactions
450
Medicare Patients
7,746
Medicare Billing
$892,148
Payment Breakdown by Category
Other$282,411 (60.5%)
Consulting$145,164 (31.1%)
Travel$30,173 (6.5%)
Food & Beverage$8,869 (1.9%)
Research$99.00 (0.0%)
Education$1.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $282,411 | 120 | 60.5% |
| Consulting Fee | $145,164 | 38 | 31.1% |
| Travel and Lodging | $30,173 | 116 | 6.5% |
| Food and Beverage | $8,869 | 174 | 1.9% |
| Unspecified | $99.00 | 1 | 0.0% |
| Education | $1.00 | 1 | 0.0% |
Payments by Type
General
$466,617
449 transactions
Research
$99.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $134,528 | 129 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $133,593 | 125 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $87,550 | 40 | $0 (2021) |
| Gilead Sciences, Inc. | $41,428 | 55 | $0 (2023) |
| Merck Sharp & Dohme LLC | $40,697 | 32 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13,005 | 18 | $0 (2022) |
| Medtronic Vascular, Inc. | $8,426 | 11 | $0 (2017) |
| Sumitomo Pharma America, Inc. | $5,637 | 9 | $0 (2023) |
| Medtronic, Inc. | $550.00 | 1 | $0 (2020) |
| Vertex Pharmaceuticals Incorporated | $500.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,880 | 67 | Actelion Pharmaceuticals US, Inc. ($34,416) |
| 2023 | $66,520 | 68 | Actelion Pharmaceuticals US, Inc. ($34,835) |
| 2022 | $43,327 | 54 | Actelion Pharmaceuticals US, Inc. ($19,053) |
| 2021 | $51,483 | 35 | United Therapeutics Corporation ($24,624) |
| 2020 | $102,071 | 41 | Bayer HealthCare Pharmaceuticals Inc. ($70,434) |
| 2019 | $27,972 | 35 | United Therapeutics Corporation ($25,577) |
| 2018 | $42,993 | 62 | Gilead Sciences, Inc. ($18,296) |
| 2017 | $61,469 | 88 | Gilead Sciences Inc ($18,729) |
All Payment Transactions
450 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $416.60 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $320.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/04/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: Cardiology | ||||||
| 10/04/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | Cash or cash equivalent | $14.10 | General |
| Category: Cardiology | ||||||
| 09/27/2024 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $44.00 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/27/2024 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $35.93 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/27/2024 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $28.94 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/27/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $9.23 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/24/2024 | United Therapeutics Corporation | TYVASO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,100.00 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,050.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/13/2024 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | In-kind items and services | $199.87 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 08/29/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $322.56 | General |
| Category: Cardiology | ||||||
| 08/29/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: Cardiology | ||||||
| 08/29/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: Cardiology | ||||||
| 08/29/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | Cash or cash equivalent | $20.88 | General |
| Category: Cardiology | ||||||
| 08/23/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,050.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: Cardiology | ||||||
| 08/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,363.00 | General |
| Category: Cardiology | ||||||
| 08/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | In-kind items and services | $996.88 | General |
| Category: Cardiology | ||||||
| 08/16/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | In-kind items and services | $817.63 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 1,806 | 2,392 | $637,828 | $157,738 |
| 2022 | 23 | 2,081 | 3,697 | $532,635 | $268,164 |
| 2021 | 28 | 2,086 | 3,272 | $476,802 | $251,221 |
| 2020 | 29 | 1,773 | 2,797 | $425,523 | $215,024 |
Total Patients
7,746
Total Services
12,158
Medicare Billing
$892,148
Procedure Codes
112
All Medicare Procedures & Services
112 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 260 | 439 | $154,089 | $42,651 | 27.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 70 | 125 | $111,330 | $20,096 | 18.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 150 | 150 | $79,500 | $18,252 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 93 | 126 | $59,220 | $17,133 | 28.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 77 | 77 | $51,282 | $12,620 | 24.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 44 | 73 | $24,601 | $6,556 | 26.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 209 | 238 | $27,132 | $4,729 | 17.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 30 | $19,295 | $3,941 | 20.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 54 | 54 | $8,532 | $3,881 | 45.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 63 | $14,868 | $3,798 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 36 | $8,604 | $2,482 | 28.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 44 | 65 | $5,850 | $2,427 | 41.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 54 | 55 | $9,735 | $2,384 | 24.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 54 | 55 | $9,515 | $2,283 | 24.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 63 | 63 | $4,158 | $1,861 | 44.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 61 | 63 | $12,033 | $1,859 | 15.5% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 17 | 17 | $7,293 | $1,627 | 22.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 109 | 181 | $2,670 | $1,336 | 50.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 52 | 53 | $5,830 | $1,333 | 22.9% |
| 94762 | Test to measure oxygen level in blood using ear or finger device continuously overnight | Office | 2023 | 60 | 70 | $5,670 | $1,319 | 23.3% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 14 | 17 | $4,692 | $1,075 | 22.9% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 59 | 101 | $2,222 | $837.29 | 37.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 18 | 27 | $2,160 | $794.64 | 36.8% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 14 | 22 | $1,650 | $709.27 | 43.0% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 27 | 41 | $2,009 | $579.33 | 28.8% |
About Dr. Jeremy Feldman, M.D
Dr. Jeremy Feldman, M.D is a Critical Care Medicine healthcare provider based in Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689681025.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeremy Feldman, M.D has received a total of $466,716 in payments from pharmaceutical and medical device companies, with $70,880 received in 2024. These payments were reported across 450 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($282,411).
As a Medicare-enrolled provider, Feldman has provided services to 7,746 Medicare beneficiaries, totaling 12,158 services with total Medicare billing of $892,148. Data is available for 4 years (2020–2023), covering 112 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Bend, OR
- Active Since 08/01/2006
- Last Updated 12/17/2024
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1689681025
Products in Payments
- UPTRAVI (Drug) $107,701
- TYVASO (Drug) $42,017
- Adempas (Drug) $26,800
- ORENITRAM (Drug) $20,985
- WINREVAIR (Biological) $20,072
- Letairis (Drug) $19,430
- REMODULIN (Drug) $18,294
- OPSUMIT (Drug) $12,291
- NONE (Drug) $12,287
- OFEV (Drug) $7,428
- Veklury (Drug) $2,070
- FLOWTRIEVER CATHETER, S (Device) $296.06
- Impella (Device) $63.00
- TRELEGY ELLIPTA (Drug) $35.10
- BROVANA (Drug) $34.37
- TEZSPIRE (Biological) $30.87
- MONOFERRIC (Drug) $29.87
- Utibron (Drug) $25.91
- Pulmonx Endobronchial Valve EBV (Device) $22.89
- Arikayce (Drug) $20.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Bend
Kevin Sherer, Md, MD
Critical Care Medicine — Payments: $48,759
Critical Care Medicine $48,759
Dr. Daniel Sedehi, Md, MD
Critical Care Medicine — Payments: $22,441
Critical Care Medicine $22,441
Juan Tamariz-Loor, Md, MD
Critical Care Medicine — Payments: $7,341
Critical Care Medicine $7,341
Dr. Gregory Blair, M.d, M.D
Critical Care Medicine — Payments: $1,146
Critical Care Medicine $1,146
Dr. Ryan Nelson, M.d, M.D
Critical Care Medicine — Payments: $630.05
Critical Care Medicine $630.05
Daniel Hagg, Md, MD
Critical Care Medicine — Payments: $583.03
Critical Care Medicine $583.03